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AbstrAct
Introduction Emergency percutaneous coronary 
intervention (PCI) of the culprit lesion for patients with 
acute myocardial infarctions is an accepted practice. A 
majority of patients present with multivessel disease with 
additional relevant stenoses apart from the culprit lesion. 
In haemodynamically stable patients, there is increasing 
evidence from randomised trials to support the practice 
of immediate complete revascularisation. However, in the 
presence of cardiogenic shock, the optimal management 
strategy for additional non-culprit lesions is unknown. A 
multicentre randomised controlled trial, CULPRIT-SHOCK, is 
examining whether culprit vessel only PCI with potentially 
subsequent staged revascularisation is more effective 
than immediate multivessel PCI. This paper describes the 
intended economic evaluation of the trial.
Methods and analysis The economic evaluation will be 
conducted using a pre-trial decision model and within-
trial analysis. The modelling-based analysis will provide 
expected costs and health outcomes, and incremental 
cost-effectiveness ratio over the lifetime for the cohort 
of patients included in the trial. The within-trial analysis 
will provide estimates of cost per life saved at 30 days 
and in 1 year, and estimates of health-related quality of 
life. Bootstrapping and cost-effectiveness acceptability 
curves will be used to address any uncertainty around 
these estimates. Different types of regression models 
within a generalised estimating equation framework 
will be used to examine how the total cost and 
quality-adjusted life years are explained by patients’ 
characteristics, revascularisation strategy, country and 
centre. The cost-effectiveness analysis will be from the 
perspective of each country’s national health services, 
where costs will be expressed in euros adjusted for 
purchasing power parity.
Ethics and dissemination Ethical approval for the 
study was granted by the local Ethics Committee at each 
recruiting centre. The economic evaluation analyses will 
be published in peer-reviewed journals of the concerned 
literature and communicated through the profiles of the 
authors at www. twitter. com and www. researchgate. net.
trial registration number NCT01927549; Pre-results.
bAckground
Among all the patients admitted to hospi-
tals in Europe with acute myocardial 
infarction (AMI),1 about 7%–8% develop 
cardiogenic shock and most of these patients 
(about 70%–80%) have multivessel coro-
nary artery disease.2–4 In these patients, early 
mechanical reperfusion of the culprit lesion 
by percutaneous coronary intervention 
(PCI) is considered to be the most effec-
tive and important therapeutic measure. 
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Protocol
strengths and limitations of this study
 ► First economic evaluation of culprit only 
percutaneous coronary intervention (PCI) compared 
with immediate multivessel PCI within a trial with 
patients in cardiogenic shock.
 ► The economic evaluation within the pragmatic 
multicountry trial design will enrich the external 
validity of results.
 ► The methodological approach of a ‘fully pooled with 
multicountry costing’ will address heterogeneity in 
costs of resource use and drug prices across trial 
participating countries.
 ► A pre-trial model is considered to extrapolate within-
trial results in the long term for a lifetime economic 
evaluation.
 ► Data completeness and plausibility checks are 
instituted in the electronic case report form to 
ensure robust and complete data collection.
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However, even with advanced haemodynamic support, 
the mortality rate remains as high as 40%–70%.2–7 Imme-
diate multivessel PCI may prevent potentially recurrent 
ischaemic cardiac events and improve outcomes but may 
also be associated with a higher risk of serious adverse 
events including iatrogenic myocardial infarction, 
contrast-induced nephropathy and an increased need 
for subsequent revascularisation procedures due to rest-
enosis.8
There are uncertainties and differences regarding 
patient management. Current guideline recommen-
dations in Europe suggest that primary PCI should be 
restricted to the culprit vessel with exception of cardio-
genic shock and continuing ischaemia after PCI of the 
culprit lesion,8–10 while there are no specific recommen-
dations by the American Heart Association/American 
College of Cardiology.1 8
Given the lack of randomised clinical trial data, a collab-
orative consortium of European partners (in Austria, 
France, Germany, Italy, Lithuania, The Netherlands, 
Poland, Slovenia, Belgium, Switzerland and UK) has been 
formed to conduct a large-scale prospective randomised, 
controlled, international multicentre trial.8 The trial is an 
attempt to determine the optimal percutaneous revascu-
larisation strategy in patients with AMI and multivessel 
disease complicated by cardiogenic shock (see ref. 8 for 
further detail on trial design). The decision problems 
that the trial attempts to address are:
 ► Whether performing immediate culprit vessel only 
PCI with potential subsequent staged revascularisa-
tion reduces the incidence of the combined endpoint 
of 30-day mortality and severe renal failure (requiring 
renal replacement therapy) compared with immedi-
ate multivessel percutaneous revascularisation.
 ► Whether immediate culprit vessel only PCI improves 
quality of life compared with immediate multivessel 
percutaneous revascularisation.
 ► Whether culprit vessel only PCI with potential subse-
quent staged revascularisation is cost-effective com-
pared with immediate multivessel revascularisation.
This study protocol addresses the third decision 
problem. The need for a cost-effectiveness analysis (CEA) 
relies on the fact that we could expect culprit vessel 
revascularisation to be a safer strategy for patients with 
cardiogenic shock and, at the same time, there are reasons 
to anticipate higher costs due to the need for subsequent 
staged revascularisation and different resources like 
mechanical support devices.
MEthods
Population, setting and location, and comparators
The details of the methods and design of the trial have 
been published previously in a separate manuscript.8 The 
CULPRIT-SHOCK study is a prospective, randomised, 
open-label trial in patients with multivessel coronary 
artery disease and AMI including both ST-elevation and 
non-ST-elevation myocardial infarction complicated by 
cardiogenic shock. The trial will recruit 706 patients with 
AMI with cardiogenic shock and multivessel disease, half 
of this population will be receiving culprit vessel only 
PCI with potentially subsequent staged revascularisation 
and the rest will receive immediate multivessel revascu-
larisation by PCI. This international trial is conducted in 
approximately 100 centres of the 11 participating coun-
tries.8
type of economic evaluation
The economic evaluation will be composed of both CEA 
and cost-utility analysis (CUA). The CEA will use the 
outcome measures of 30-day mortality and renal failure. 
Quality-adjusted life years (QALYs) will be used for the 
CUA.
time horizon
The CEA will rely on the information collected during 
the first 30-day period after revascularisation. On the 
contrary, two different CUAs will be considered: a with-
in-trial economic evaluation using information collected 
during a 1-year follow-up period and economic evalua-
tion based on a long-term model.
study perspective
The economic evaluation will have health systems and 
societal perspectives. Initially, the costs for each type of 
revascularisation strategies will be derived from Germa-
ny’s national health service perspective. In addition, the 
perspective of each country’s national health service will 
also be considered.
discount rate
The base case analysis rate that will be used for discounting 
future costs and effects will be 3% in accordance with 
the Institute for Quality and Efficiency in Health Care 
guideline.11 The discounting rate will be adapted to suit 
different payers’ perspectives in the 11 trial participating 
countries.
Identification, measurements and valuation of outcomes
The health outcome measures that will be used for the 
economic evaluation and endpoints of the data collection 
are presented in table 1.
The EuroQol five-dimensions (EQ-5D) three-level12 
will be used to assess the quality of life for each patient. 
EQ-5D data will be collected at 1 month post procedure 
(follow-up on 30 days), 6 and 12 months after randomisa-
tion. The utility weights for each health states at different 
periods will be obtained by using the EQ-5D index tariff 
developed for the German population. Mean differences 
in EQ-5D between the groups will be estimated and will 
be presented with statistical tests of significance for the 
different follow-up periods. Country-specific tariffs will 
also be analysed. The probable imbalances in baseline 
utility will be adjusted to estimate differential mean 
QALYs as suggested by Manca et al.13
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Table 1 The outcome measures and means of data collection
Outcome measures Means of data collection Time of collection
Mortality eCRF 30 days after randomisation, 6 and 12 months follow-up
Severe renal failure* eCRF 30 days after randomisation, 6 and 12 months follow-up
Heart failure* eCRF 30 days after randomisation, 6 and 12 months follow-up
MACE† eCRF 30 days after randomisation, 6 and 12 months follow-up
Quality of life eCRF 30 days after randomisation, 6 and 12 months follow-up
*Heart and renal failure are health conditions for which specific long-term treatment is needed.
†Major advanced cardiac events (myocardial infarction, non-fatal stroke and need for repeat revascularisation).
eCRF, electronic case report form; MACE, major advanced cardiac events.
Identification, measurement and valuation of resource use
The primary objective of the cost analysis will be 
identifying, quantifying and valuing resources use accom-
panying the revascularisation strategies. The registry data 
on patients not randomised for the trial but collected 
within the project will also be used for supplementary 
information on resources use. The costs will be classified 
into the following major groups:
Intervention costs
The main items of the intervention costs (CInt) will include 
the resource use for index revascularisation procedure 
(PCI) and repeat/staged revascularisation procedure 
(PCI or coronary artery bypass surgery (CABG)). The 
resource use for investigations (eg, non-invasive evalua-
tion for residual myocardial ischaemia at 1–4 weeks post 
index PCI of the culprit lesion such as nuclear perfusion 
scintigraphy, stress echocardiography or stress MRI) and 
other procedures (angiography, stenting, internal cardio-
verter defibrillator implants, extracorporeal membrane 
oxygenation, intra-aortic balloon pump, left ventric-
ular assist devices, heart transplantation), treatments of 
renal failure, heart failure and major advanced cardiac 
events (MACE) will constitute the cost of health services 
use (CHServ). The electronic case report forms (eCRFs) 
are used for collecting all the above mentioned resources.
Cost of medication
Information on use of medications during the trial period 
is collected in eCRF to estimate the cost of medication 
(CMed).
Loss of productivity
Data on loss of days of work are collected using the eCRF. 
The cost of productivity loss (CostLp) for trial patients 
will be calculated using a human capital approach.
Table 2 presents the resources items, data collection 
and source of unit cost. The costs will be converted into 
base year 2014 and will then be converted into euros 
using consumer price index and purchasing power parity 
conversion rates, respectively, provided by the Organisa-
tion for Economic Co-operation and Development.
The total cost (CTot) for each strategy will be given by 
the next equation:
 CTot = CInt + CHServ + CMed + CostLp. 
The within-trial analyses of this multinational economic 
evaluation will employ a ‘multicountry costing’; that is, the 
source of clinical effectiveness and resource use data will 
be pooled, combined with country-specific unit costs.14 
This will be contrasted with a ‘single-country’ approach 
of applying a single country’s unit costs to the whole trial 
dataset.15
Modelling
A pre-trial decision model will be used for the long-term 
analysis.
Initially, the modelling exercise for the economic eval-
uation will be from Germany perspective and will be later 
adapted for the rest of the trial participating countries 
keeping the basic structure unchanged.
The population that will be considered in the model is 
similar to the patients included in the trial. The model 
is presented in schematic diagrams in figures 1 and 2. 
The figures show the stages or pathways of the patients. 
First stage (figure 1—initial procedure decision) is where 
the patients are provided with the revascularisation treat-
ments. At this stage, the model will be based on a decision 
tree for the first year after randomisation. Assuming that 
the diagnostic angiography can correctly identify culprit 
lesions, the two options of treatment that are available for 
the patients are (1) immediate multivessel revascularisa-
tion of all vessels by PCI or (2) revascularisation by PCI 
of culprit lesion only and potentially staged revascularisa-
tion (either by PCI or CABG).
The patients after the index revascularisation and the 
planned staged revascularisation can die or can be alive 
with initial success of the treatment. Within 30 days, 
patients can survive with index revascularisation or can 
die. It is assumed that those who survive can either remain 
stable and alive or (1) can have renal failure or (2) can 
suffer from MACE (viz. ie, myocardial infarction/repeat 
infarction, stroke and revascularisation) or (3) have heart 
failure or (4) die due to cardiac events or other causes. 
Patients who survive initially from all these health states 
will move to the next stage shown in figure 2.
The next stage of the model (figure 2), a Markov model, 
shows the different health states for the patients for their 
lifetime period. It is assumed that the patients can move 
to one of the five different health states (similar to what is 
noted in figure 1). A patient who is alive and stable after 
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Table 2 The resource use, cost measures and means of data collections in Germany
Resources use and costs measures Means for data collection Time of collection
Source of data 
for unit cost
Intervention
  Multivessel revascularisation eCRF Baseline, 30 days, 6 and 12 months InEK
  Culprit vessel revascularisation eCRF Baseline, 30 days, 6 and 12 months InEK
  Repeat revascularisation eCRF Baseline, 30 days, 6 and 12 months InEK
Health services use
  Investigations eCRF Baseline, 30 days, 6 and 12 months InEK
  Other procedures
   Angiography eCRF Baseline, 30 days, 6 and 12 months InEK
   Stenting eCRF Baseline, 30 days, 6 and 12 months InEK
   ICD implant eCRF Baseline, 30 days, 6 and 12 months InEK
   ECMO eCRF Baseline, 30 days, 6 and 12 months InEK
   IABP eCRF Baseline, 30 days, 6 and 12 months InEK
   LVAD eCRF Baseline, 30 days, 6 and 12 months InEK
   Heart transplant eCRF Baseline, 30 days, 6 and 12 months InEK
  Treatment for
   MACE eCRF Baseline, 30 days, 6 and 12 months InEK
   Renal failure eCRF Baseline, 30 days, 6 and 12 months InEK
   Heart failure eCRF Baseline, 30 days, 6 and 12 months InEK
   Stroke eCRF Baseline, 30 days, 6 and 12 months InEK
  Medication eCRF Baseline, 30 days, 6 and 12 months InEK
Loss of Productivity eCRF 6 and 12 months follow-up Destatis
Destatis, Federal Statistical Office; ECMO, extracorporeal membrane oxygenation; eCRF, electronic case report form; InEK, Institute for the 
Hospital Remuneration System; IABP, intra-aortic balloon pump; ICD, internal cardioverter defibrillator; LVAD, left ventricular assist device; 
MACE, major advanced cardiac events. 
1 year may suffer MACE and go back to alive and stable 
health state. It is also assumed that patients after having 
heart or renal failure can suffer from MACE and can 
go back and remain stable with the condition. Only the 
patients who remain alive and stable are assumed to 
transit to health states of renal or heart failure but the 
opposite pathway is not permitted. Finally, patients can 
also end up at absorbing health state death from all those 
health states.
Model parameters
The Markov model will be populated with transition 
probabilities and with cost and utility data conditional 
on health status. For the Markov stage, the transitions 
to different health states will be conditional on previous 
health state and on the type of revascularisation. The 
cycle length will be assumed to be 1 month. It is expected 
that there will be utility decrements accompanying renal 
failure, the possible adverse cardiac events and hence 
loss of QALYs. Values of the effectiveness parameters, 
transition probability of moving from health states and 
utilities will be based on the review of selected studies on 
clinical effectiveness and economic evaluations studies, 
previous reviews and expert advice from clinicians from 
trial participating countries. The model’s parameters are 
listed in online supplementary annex 1.
Statistical analyses of the trial data and registry data 
will provide more information that will enable us to have 
robust values for the pre-trial model parameters. With the 
survival analysis using trial data, the survival probability 
will be calculated to populate the model with revised 
transition probability to deaths that can be attributed to 
clinical conditions and MACE. The validation of model 
will be conducted by looking at the internal and external 
validity.16
AnAlysIs
Within-trial analysis
Statistical analyses and CEAs will be carried out using 
trial data where information on a range of resource 
use and outcome measures are collected at the patient 
level across the trial participating countries. The basis 
of analysis will be intention to treat.
Handling missing data
Cost data are characterised by severe skewness in their 
probability distribution17 18 and it may be the case 
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Figure 1 Post index revascularisation, from 30 days to 1 year. AMI, acute myocardial infarction; MACE, major advanced 
cardiac events.
that a few patients may have very high resource use 
and hence high cost, and a large number of patients 
may have low cost. There may be incomplete data 
and cost data can be missing at individual item level. 
Appropriate methods will be used to treat missing 
information. Multiple imputation method has been 
widely recommended by experts and by ISPOR17 19–21 as 
this method helps to reveal the uncertainty that occurs 
where the missing data are replaced in the imputation 
process.19 A descriptive analysis will be undertaken to 
check the nature of missing data before such method is 
used. As suggested by Faria et al,22 a sensitivity analysis 
will be conducted to examine the impact of alternative 
assumptions about the mechanism of missing data.
Base case analysis and regression
Baseline characteristics of the patients in the two 
different intervention groups will be summarised. 
Differences in resource use and costs between the 
two groups will be tested using two-sample t-tests (or 
non-parametric equivalents) and Χ2 tests for contin-
uous and categorical variables, respectively. The mean 
costs of resource use in each arm of the care interven-
tion and the differences in costs between the two arms 
will be calculated with 95% CIs. Similarly, the mean 
QALY score for each group will be estimated.
Regression analyses will be conducted to examine 
how the total cost and health outcomes may be 
explained by the patient characteristics, interven-
tion type, country and centres. Different types of 
models will be explored within generalised estimating 
equation framework that can take into account the 
clustering of the data within the countries.
CEA with trial data
CEA will be presented as incremental cost per 30-day 
mortality averted and incremental cost per QALY gained. 
The incremental cost-effectiveness ratio (ICER) will be 
calculated as:
 ICER =
Costco−Costmv
QALYco−QALYmv 
where Costco is the total cost of treating the patients by 
revascularisation of the culprit vessel only and Costmv 
is the total cost of treating the patients by immediate 
multivessel revascularisation. QALYco is total QALYs for the 
patients having culprit vessel revascularisation only and 
QALYmv is total QALYs for the patients having immediate 
multivessel revascularisation.
Subgroup analyses for gender, age groups (<50 years, 
50–75 years, >75 years) and patients with diabetes will be 
considered to address the issue of underlying heteroge-
neity.23 24 The results of the cost-effectiveness including the 
subgroup and sensitivity analyses will be presented both 
in terms of point estimates and cost-effectiveness planes, 
and cost-effectiveness acceptability curves (CEACs).25
The two revascularisation strategies will be also compared 
on the basis of incremental net monetary benefits. The 
net monetary benefit of revascularisation multivessel 
(strategy 1) or revascularisation of culprit vessel only 
(strategy 2) will be calculated as: the mean QALYs (qi) 
multiplied by the acceptable threshold values for a QALY 
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Figure 2 Post 1 year and end of life—Markov model. MACE, major advanced cardiac events.
(λ), minus the mean cost of implementing the strategy.1 
This can be given as:
 NMBi = λqi− ci, where i = strategy 1 or strategy 2. 
The threshold value (λ) should be interpreted as the 
monetary value of a QALY. Different values will be used 
for different countries assuming that this parameter will 
be different or may be unknown.
the effectiveness measure and cEA in the model-based 
analysis
The effectiveness measure for economic outcomes in our 
model-based analysis will be QALYs. Model results will 
provide estimates for the ICER considering long-term 
health outcomes and costs.
The results of the economic evaluation including the 
subgroup and sensitivity analyses will be presented in 
terms of point estimates, cost-effectiveness planes and 
CEACs.25
handling uncertainty
To present, the robustness of our estimation of cost-effec-
tiveness non-parametric bootstrapping techniques will be 
used.26 CEACs will illustrate the uncertainty surrounding 
the estimate of cost-effectiveness.25 This curve will show us 
the probability of culprit only revascularisation strategy to 
be cost-effective compared with the immediate multivessel 
revascularisation strategy for a range of monetary values 
of a QALY. Both probabilistic and deterministic sensitivity 
analyses will be used to explore statistical and other forms 
of uncertainty arising from the imprecision with which 
model parameters are estimated.
Value of information
Value of information analysis will also be conducted. 
Such analysis will help to determine whether additional 
research will be required to inform the future decision27 
about immediate revascularisation in case of acute AMI 
with multivessel diseases and complicated by cardiogenic 
shock.
EthIcs And dIssEMInAtIon
Ethical approval for the study was granted by the local 
Ethics Committee at each recruiting centre. Ethical 
approvals by the lead ethical committees for each country 
are: (a) Germany, Ethical Committee at the University 
of Luebeck: reference number 13-142; (b) Netherlands, 
Medisch Ethische Toetsingscommissie (Academisch 
Medisch Centrum, University of Amsterdam): refer-
ence number E2-170; (c) Austria, Magistratsabteilung 
15-Gesundheitsdienst der Stadt Wien: reference number 
EK-13-241-0214; (d) Lithuania, Lietuvos Bioetikos 
Komitetas: reference numbers L-14-01/1 and L-14-01/2; 
(e) France, Comité de Protection des Personnes, Ile de 
France 1: reference number 2014-janvier.-13464; (f) 
Poland, Klinika Intensywnej Terapii Kardiologicznej: 
reference number IK-NP-0021-97/1408/13; (g) Slovenia, 
Komisija Republike Slovenije za medicinsko etiko: refer-
ence numbers 63/12/13 and 60/09/14; (h) Switzerland, 
Kantonale Ethikkommission Bern (KEK): reference 
number 041/14; (i) Italy, Comitato Etico Provinciale 
di Reggio Emilia: reference number 2013/0029992; (j) 
Belgium, Universiteit Antwerpen (Ethics Committee): 
reference number 15/11/116; (k) UK, National Health 
Service (NHS) (Scotland Research Ethics Committee): 
reference number 14/YH/0116; and (l) Scotland, 
NHS (Scotland rEsearch Ethics Committee): reference 
number 14/SS/0072.
The economic evaluation analyses will be published in 
peer-reviewed journals of the concerned literature and 
communicated through the profiles of the authors at 
www. twitter. com and www. researchgate. net.
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dIscussIon
This will be the first economic evaluation where effec-
tiveness of culprit only PCI with potential staged 
revascularisation will be tested against immediate 
multivessel PCI within a trial. A pre-trial decision model 
will provide estimates of incremental cost per QALY 
generated by culprit vessel revascularisation over the prac-
tice of all vessel revascularisation. According to a previous 
analysis performed by us, based on a simulation of this 
model populated with parameters from the literature, 
an ICER of about £2000/QALY is expected. However, 
there is a large uncertainty around these estimates since 
existing evidence on the two strategies compared is based 
on observational data rather than on randomised control 
trials. We acknowledge that parameters could be biased 
and changing just one parameter (eg, probability of 
MACE, or renal failure or cost of MACE) could increase 
the ICER to about £12 000.
On the contrary, the within-trial analysis would help 
to obtain robust values for the pre-trial model param-
eters and the survival analysis will provide revised 
transition probability to deaths that can be attributed 
to clinical conditions and MACE. Transferability of the 
decision-analytical model can be improved by using the 
jurisdiction-specific price weights and baseline risk of 
health states.
The results on predicted costs and outcomes from trial-
based economic analysis will help to conduct extrapolated 
analysis beyond the trial period using the decision model 
incorporating the sensitivity analyses and subgroup anal-
ysis.
strengths
This economic analysis of the largest randomised trial in 
cardiogenic shock will provide detailed health economic 
analyses further supporting potential treatment strategies 
in cardiogenic shock. The economic evaluation within 
the pragmatic multicountry trial design will enrich the 
external validity. This will enable us to assess the value 
of the revascularisation strategies for patients with cardio-
genic shock in a real-world scenario.
limitations
Given that there are differences in the health systems and 
reimbursement policy in the trial participating countries, 
potential differences in the unit prices of similar health-
care resources and medications are expected to be found. 
Trial-wide estimates of CEAs will suffer from problems 
associated with heterogeneity in costs of resource use and 
drug prices across trial participating countries. The meth-
odological approach of a ‘fully pooled with multicountry 
costing’ framework14 will address this potential problem.
There is a particular challenge with respect to data 
collection given that the existence of missing informa-
tion could affect the validity of the results. In that case, 
statistical techniques will be used to handle missing data. 
Nonetheless, an automated data check for completeness 
and data plausibility has been instituted in the eCRF to 
ensure robust and complete data collection. Further-
more, monitoring ensures data completeness and data 
plausibility—a final close-out monitoring visit is manda-
tory for all centres. In addition, case payment is only 
performed if all data are complete in the eCRF and data 
are checked for plausibility.
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